RT Journal Article SR Electronic T1 A Predictive Model to Identify Complicated Clostridiodes difficile Infection JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.05.18.22275113 DO 10.1101/2022.05.18.22275113 A1 Berinstein, Jeffrey A. A1 Steiner, Calen A. A1 Rifkin, Samara A1 Perry, D. Alexander A1 Micic, Dejan A1 Shirley, Daniel A1 Higgins, Peter D.R. A1 Young, Vincent B. A1 Lee, Allen A1 Rao, Krishna YR 2022 UL http://medrxiv.org/content/early/2022/05/22/2022.05.18.22275113.abstract AB Background Clostridioides difficile infection (CDI) is a leading cause of healthcare-associated infections and may result in organ dysfunction, colectomy, and death. We recently showed that published risk scores to predict severe complications from CDI demonstrate poor performance upon external validation. We hypothesized that building and validating a model using geographically and temporally distinct cohorts would more accurately identify patients at risk for complicated CDI.Methods We conducted a multi-center retrospective cohort study of adult subjects diagnosed with CDI in the US. After randomly partitioning the data into training/validation set, we developed and compared three machine learning algorithms (Lasso regression, random forest, stacked ensemble models) with 10-fold cross-validation that used structured EHR data collected within 48 hours of CDI diagnosis to predict disease-related complications from CDI (intensive care unit admission, colectomy, or death attributable to CDI within 30 days of diagnosis). Model performance was assessed using area under the receiver operating curve (AUC).Results A total of 3,762 patients with CDI were included of which 218 (5.8%) had complications. Lasso regression, random forest, and stacked ensemble models all performed well with AUC ranging between 0.89-0.9. Variables of importance were similar across models, including albumin, bicarbonate, change in creatinine, systolic blood pressure, non-CDI-related ICU admission, and concomitant non-CDI antibiotics. Sensitivity analyses indicated that model performance was robust even when varying derivation cohort inclusion and CDI testing approach.Conclusion Using a large heterogeneous population of patients, we have developed and validated a prediction model based on structured EHR data that accurately estimates risk for complications from CDI.Key Points Machine learning models using structured electronic health records can be leveraged to accurately predict risk of severe complications related to Clostridiodes difficile infection, including intensive care unit admission, colectomy, and/or death.Competing Interest StatementPDRH received consulting fees from AbbVie, Amgen, Genentech, JBR Pharma and Lycera. JAB received consulting fees from Buhlmann Diagnostic Corp. KR is supported in part from an investigator-initiated grant from Merck & Co, Inc.; he has consulted for Bio-K* International, Inc., Roche Molecular Systems, Inc., Seres Therapeutics, Inc. and Summit Therapeutics, Inc. All other authors report no disclosures. Funding StatementThis study was supported by the National Institutes of Health grants HS027431 (to KR) and DK124567 (to AAL).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review boards at the University of Michigan, University of Chicago, and University of Wisconsin gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsAUCarea under the receiver operator characteristic curveCDIClostridiodes difficile infectionEHRelectronic health recordsICUintensive care unit